蛋白激酶C活性与卵巢癌多药耐药性的相关性  

Correlation between protein kinase C activity and multidrug resistance in ovarian cancer

作　　者：何社红[1] 薛聪玲[1] 

机构地区：[1]洛阳市中心医院妇产科,河南洛阳471009

出　　处：《新乡医学院学报》2017年第7期660-662,共3页Journal of Xinxiang Medical University

摘　　要：目的探讨蛋白激酶C(PKC)的活性与卵巢癌(OC)多药耐药性(MDR)的关系。方法选取2014年1月至2016年12月洛阳市中心医院手术切除的OC组织标本69例,体外培养肿瘤细胞,采用四甲基偶氮唑蓝法进行体外药物敏感性试验,酶联免疫吸附试验检测OC组织中PKC活性,分析PKC活性与OC MDR的关系。结果体外药物敏感性试验结果显示,69例OC组织中,对顺铂、阿霉素、环磷酰胺3种药物联合化学治疗高度敏感13例(18.84%),中度敏感19例(27.54%),低度敏感16例(23.19%),耐药21例(30.43%)。高度敏感、中度敏感、低度敏感和耐药的OC组织中PKC活性分别为(1.31±0.09)、(11.69±1.02)、(13.87±1.37)、(19.16±3.15)μmol·mgprot^(-1)·h^(-1),耐药性越强,卵巢癌组织中PKC活性越强(P<0.01)。Ⅰ、Ⅱ、Ⅲ、Ⅳ期OC组织中PKC活性分别为(3.79±1.24)、(8.02±1.57)、(9.37±1.16)、(9.93±1.41)μmol·mgprot^(-1)·h^(-1),临床分期越高,OC组织中PKC活性越强(P<0.05)。G1、G2、G3级OC组织中PKC活性分别为(7.23±1.02)、(9.64±1.71)、(12.39±1.26)μmol·mgprot^(-1)·h^(-1),病理分级越高,OC组织中PKC活性越强(P<0.05)。结论 PKC活性越高,OC的MDR越强,PKC可能参与了OC的MDR机制;OC组织中PKC活性检测可以作为预测化学治疗敏感性的指标之一。Objective To investigate the relationship between the activity of protein kinase C（ PKC） and multidrug resistance（ MDR） in ovarian cancer（ OC）. Methods Sixty-nine specimens of OC from January 2014 to December 2016 in Luoyang Central Hospital were selected. The tumor cells were cultured in vitro. The MDR of OC was detected by methyl tetrazolium blue method,and the activity of PKC in OC tissues was detected by enzyme linked immunosorbent assay. The relationship between PKC activity and MDR of OC was analyzed. Results The drug sensitivity test in vitro showed that among the 69 cases of OC tissues,cisplatin,adriamycin and cyclophosphamide combined chemotherapy was highly sensitive in 13 cases（ 18. 84%）,moderately sensitive in 19 cases（ 27. 54%）,low sensitive in 16 cases（ 23. 19%） and drug resistant in 21 cases（ 30. 43%）. The activity of PKC in highly sensitive,moderately sensitive,low sensitive and drug resistant OC tissues was（ 1. 31 ± 0. 09）,（ 11. 69 ± 1. 02）,（ 13. 87 ± 1. 37） and（ 19. 16 ± 3. 15） μmol·mgprot^-1·h^-1respectively; with the increase of drug resistance,the activity of PKC in OC tissues was higher（ P〈0. 01）. The activity of PKC in OC tissues of stageⅠ,Ⅱ,Ⅲ and Ⅳ was（ 3. 79 ± 1. 24）,（ 8. 02 ± 1. 57）,（ 9. 37 ± 1. 16） and（ 9. 93 ± 1. 41） μmol·mgprot^-1·h^-1respectively; with the increase of clinical stage,the activity of PKC in OC tissues was higher（ P〈0. 05）. The activity of PKC in grade G1,G2 and G3 OC tissues was（ 7. 23 ± 1. 02）,（ 9. 64 ± 1. 71） and（ 12. 39 ± 1. 26） μmol·mgprot^-1·h^-1respectively; with the increase of the pathological grade,the activity of PKC in OC tissues was higher（ P〈0. 05）. Conclusions With the increase of the activity of PKC,the MDR of OC is more. PKC may be involved in the MDR mechanism of OC. The detection of PKC activity in OC tissues can be used as an indicator of sensitivity to chemotherapy.

关 键 词：卵巢癌 蛋白激酶C 多药耐药 

分 类 号：R737.31[医药卫生—肿瘤]